Category Archives: IP

Does IP Stimulate Growth and Create Jobs? New European Data Says Yes

A new study shows the importance of intellectual property in stimulating jobs and productivity in the EU. Surprisingly, it illustrates pharma’s established position as an IP powerhouse, evidence that adds conviction to the views expressed by GSK CEO Andrew Witty and other industry leaders that growing cuts on drug pricing are limiting an industry that […]
Also posted in Europe | Tagged , , , , , , , , | 1 Comment

There's New Hustle in Myeloma

The Multiple Myeloma Research Foundation (MMRF) has launched a new initiative to increase the pace of innovation in myeloma research through faster cures and more efficient, timely trials for patients. Founded in 1998, MMRF is the leading non-profit organization in the myeloma space, dedicating 90 per cent of its funding to medical research, disease awareness […]
Also posted in Events, FDA, R&D | Tagged , , , , , , | Leave a comment

Roche Jumps into Medicines Patent Pool with Pricing and Licensing Deal

Roche this week has announced a partnership with the UN-backed Medicines Patent Pool (MPP) to provide its drug valganciclovir, better known in the developed world as Valcyte, in 138 countries for a reduced price. In addition to making the drug available in these markets for up to 90% cheaper than current price, Roche has decided […]
Also posted in Corporate Responsibility, Deals, Emerging Markets, Global, Market Access, pricing | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

Breaching the Great Wall: Major Pharma Changes Proposed in China

With a revision of China’s basic drug approval law now underway, a multinational team of experts is proposing major changes to make the country a world class player in innovation. Dr. Wang Chenguang, Dean of Tsinghua Law School Behind the vaulting growth statistics that make China the centerfold in Big Pharma’s global playbook is a […]
Also posted in compliance, Emerging Markets, Global, R&D, Regulatory | Tagged , , , , , , , , , , | 3 Comments

FTC v. Actavis: Supreme Court Decision—The Rule of “No” Reason

by Traci Medford-Rosow and Peter Richardson On June 17, 2013 the Supreme Court decided FTC v. Actavis by a 5-3 vote. Justice Breyer delivered the majority opinion with Justices Kennedy, Ginsburg, Sotomayor and Kagan concurring. Chief Justice Roberts filed the dissenting opinion in which Justices Scalia and Thomas joined. For unstated reasons, Justice Alito took […]
Also posted in Legal, Market Access, Op-Ed, pricing, Regulatory, Strategy | Tagged , , , | 2 Comments
  • Categories

  • Meta